Long-Term Outcomes after Radical Prostatectomy Performed in a Community-Based Health Maintenance Organization

Cancer

Volumn 100, Issue 2, 2004, Pages 300-307

  Zhang, Ying ^a   Glass, Andrew ^b   Bennett, Nicole ^b   Oyama, Karen A ^c   Gehan, Edmund ^a   Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c NONE   (United States)

Author keywords

Health maintenance organization; Prostate carcinoma; Staging; Surgery

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PRACTICE; COMMUNITY CARE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0346093903     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11886     Document Type: Article

References (22)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-T2 N-0 M-0 prostatic adenocarcinoma: long term results. J Urol. 1990;144:1180-1184.
3. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year follow up. J Urol. 1996;155:490-494.
4. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998;160:2428-2434.
5. Southwick PC, Catalona WJ, Partin AW, et al. Prediction of post-radical prostatectomy pathological outcome for Stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol. 1999;162:1346-1351.
6. Potosky AL, Merrill RM, Riley GF, et al. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res. 1999;34:525-546.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-223.
9. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
10. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996;276:615-619.
11. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528-534.
12. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001;91:2302-2314.
13. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843-848.
15. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789.
16. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med. 2002;347:839-840.
17. Ellison LM, Heaney JA, Birkmeyer JD. Trends in the use of radical prostatectomy for treatment of prostate cancer. Eff Clin Pract. 1999;2:228-233.
18. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [see comments]. JAMA. 1998;280:975-980.
19. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 1974;111:58-64.
20. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21:566-576.
21. Epstein JI, Steinberg GD. The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer. 1990;66:1927-1932.
22. Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 2002;168:1419-1422.